Register for our S/EIS Fund

We are delighted to announce that we are back with another Episode of o2h ChaiTime Season 3.

Over the recent months, we have seen three companies in o2h Ventures portfolio either list on AiM, reverse onto the TSX and others that are considering a flotation on NASDAQ. We have seen over 100 Biotech IPOs in 2020, double the year earlier. Do our British bankers still have the scars of the fallen star ‘British Biotech’ in the late 90’s and thus happy to let the best UK biotech to float for billions across the globe or are they now happy to let these demons rest.

The Panelists
Sarah Howell CEO at Arecor Therapeutics plc

Sarah Howell was appointed Chief Executive Officer of Arecor in 2015, having joined in 2011 as Chief Operating Officer and Executive Director. During her time at Arecor she led the transformation of the business into a successful clinical stage biotechnology company.

Tiffany Thorn CEO and Co-founder at BiVictriX Therapeutics plc

Tiffany is the inventor of the Bi-Cygni® approach and has led the Company since its formation in 2016, meeting key project milestones and securing £2.3m in investment to date. ​

Sharon Shacham CSO and Co-founder at Karyopharm Therapeutics Inc

Dr. Shacham co-founded Karyopharm in 2008 and has served as our Chief Scientific Officer since December 2012. She was also President of Research and Development from December 2012 to April 2021.

Peter Rands CEO and Co-founder at Small Pharma Inc

Peter is a qualified patent attorney in the UK and Europe with over 10 years’ experience in the pharmaceutical industry and has always had a passion for pharmaceutical innovation.

Sunil Shah CEO at o2h Ventures

Sunil Shah is a serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector.

Register for Invitations